Implications of Interferon-Induced Tryptophan Catabolism in Cancer, Autoimmune Diseases and Aids

  • R. R. Brown
  • Y. Ozaki
  • S. P. Datta
  • E. C. Borden
  • P. M. Sondel
  • D. G. Malone
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 294)


Tryptophan (Trp) is an indispensable amino acid required for biosynthesis of proteins, serotonin and niacin. Indoleamine 2,3-dioxygenase (IDO) is induced by infections, viruses, lipopolysaccharides, or interferons (IFNs) and this results in significant catabolism of Trp along the kynurenine (Kyn) pathway. Intracellular growth of Toxoplasma gondii and Chlamydia psittaci in human fibroblasts in vitro is inhibited by IFN-gamma and this inhibition is negated by extra Trp in the medium. Similarly, growth of a number of human cell lines in vitro is inhibited by IFN-gamma and addition of extra Trp restores growth. Thus, in some in vitro systems, antiproliferative effects of IFN-gamma are mediated by induced depletion of Trp. We find that cancer patients given Type I or Type II IFNs can induce IDO which results in decreased serum Trp levels (20-50% of pretreatment) and increased urinary metabolites of the Kyn pathway (5 to 500 fold of pretreatment). We speculate that in vivo antineoplastic effects of IFNs and clinical side effects are mediated, at least in part, by a general or localized depletion of Trp.

In view of reported increases of IFNs in autoimmune diseases and our earlier findings of elevated urinary Trp metabolites in autoimmune diseases, it seems likely that systemic or local depletion of Trp occurs in autoimmune diseases and may relate to degeneration, wasting and other symptoms in such diseases. We find high levels of IDO in cells isolated from synovia of arthritic joints.

IFNs are also elevated in human immunodeficiency virus (HIV) patients and increasing IFN levels are associated with a worsening prognosis. We propose that IDO is induced chronically by HIV infection, is further increased by opportunistic infections, and that this chronic loss of Trp initiates mechanisms responsible for the cachexia, dementia, diarrhea and possibly immunosuppression of AIDS patients. In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin. In preliminary studies, others report low levels of Trp and serotonin, and elevated levels of Kyn and quinolinic acid in AIDS patients. The implications of these data in cancer, autoimmune diseases and AIDS are discussed.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Quinolinic Acid Tryptophan Metabolism Neopterin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bender, D.A., 1987, The relative importance of dietary tryptophan and preformed nicotinic acid and nicotinamide as precursors of nicotinamide nucleotide coenzymes, in: “Progress in Tryptophan and Serotonin Research 1986”, Bender, D.A., Joseph, M.H., Kochen, W., and Steinhart, H.W., eds., de Gruyter, Berlin, pp. 159–164.Google Scholar
  2. Bernton, E.W., Meltzer, M.S., and Holaday, J.W., 1988, Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice, Science, 239: 401–404.PubMedCrossRefGoogle Scholar
  3. Beutler, B., 1988, The presence of cacheetin/tumor necrosis factor in human disease states, Am. J. Med., 85: 287–288.PubMedCrossRefGoogle Scholar
  4. Brown, R.R., Borden, E.C., Sondel, P.M., Byrne, G.I., Lee, C.M., Nunnink, J.C., Schiller, J.H., and Lehman, L.K., 1986, Effects of interferons and interleukin-2 on tryptophan metabolism in humans, J. Cell Biochem. Suppl., 10C: 230.Google Scholar
  5. Brown, R.R., Borden, E.C., Sondel, P.M., and Lee, C.M., 1987, Effects of interferons and interleukin-2 on tryptophan metabolism in humans, in: “Progress in Tryptophan and Serotonin Research 1986”, Bender, D.A., Joseph, M.H., Kochen, W., and Steinhart, H.W., eds., de Gruyter, Berlin, pp. 19–26.Google Scholar
  6. Brown, R.R., Lee, C.M., Kohler, P.C., Hank, J.A., Storer, B.E., and Sondel, P.M., 1989, Altered tryptophan metabolism in cancer patients treated with recombinant interleukin-2, Cancer Res., 49: 4941–4944.PubMedGoogle Scholar
  7. Burkes, R.L., Sherrod, A.E., Stewart, M.L., Gill, P.S., Aguilar, S., Taylor, C.R., Krailo, M.D., and Levine, A.M., 1986, Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy, Cancer, 57: 2190–2192.PubMedCrossRefGoogle Scholar
  8. Byrne, G.I., Lehmann, L.K., Kirschbaum, J.G., Borden, E.C., Lee, C.M., and Brown, R.R., 1986b, Induction of tryptophan degradation in vitro and in vivo: a gamma interferon-stimulated activity, J. Interferon Res., 6: 389–396.PubMedCrossRefGoogle Scholar
  9. Byrne, G.I., Lehmann, L.K., and Landry, G.J., 1986a, Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells, Infect. Immun., 53: 344–351.Google Scholar
  10. Carlin J.M., Borden, E.C., and Byrne, G.I., 1989b, Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-βser, J. Interferon Res., 9: 167–173.PubMedCrossRefGoogle Scholar
  11. Carlin, J.M., Borden, E.C., Sondel, P.M., and Byrne, G.I., 1989a, Interferoninduced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes, J. Leukocyte Biol., 45: 29–34.PubMedGoogle Scholar
  12. Carlin, J.M., Ozaki, Y., Byrne, G.I., Brown, R.R., and Borden, E.C., 1989c, Interferons and indoleamine 2, 3-dioxygenase: role in antimicrobial and antitumor effects, Experientia, 45: 535–541.PubMedCrossRefGoogle Scholar
  13. Cleveland, M.G., Annable, C.R., and Klimpel, G.R., 1988, In vivo and in vitro production of IFN-β and IFN-γ during graft vs. host disease, J. Immunol., 141: 3349–3356.PubMedGoogle Scholar
  14. Datta, S.P., Brown, R.R., Borden, E.C., Sondel, P.M., and Trump, D.L., 1987a, Interferon and interleukin-2 induced changes in tryptophan and neopterin metabolism: possible markers for biologically effective doses, Proc. Am. Assoc. Cancer Res., 28: 338.Google Scholar
  15. Datta, S.P., Brown, R.R., Schiller, J.H., Storer, B.E., and Borden, E.C., 1987b, Neopterin (NP) levels in cancer patients treated with human recombinant interferon (IFN). Abstract, Annual Meeting of the International Soc. for Interferon Research, Washington, D.C, November 2–6.Google Scholar
  16. de la Maza, L.M., and Peterson, E.M., 1988, Dependence on the in vitro antiproliferative activity of recombinant human g-interferon on the concentration of tryptophan in culture media, Cancer Res., 48: 346–350.Google Scholar
  17. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D., and Rosenberg, S.A., 1987, The neuropsychiatrie effects of treatment with interleukin-2 and lymphokine-activated killer cells, Ann. Internal. Med., 107: 293–300.Google Scholar
  18. DeStefano, E., Friedman, R.M., Friedman-Kien, A.E., et al., 1982, Acid-labile human leukocyte interferon in homosexual men with Kaposi’s sarcoma and lymphadenopathy, J. Infect. Dis., 146: 451–455.PubMedCrossRefGoogle Scholar
  19. Eyster, M.E., Goedert, J.J., Poon, M-C., and Preble, O.T., 1983, Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia, N. Engl. J. Med., 309: 583–586.PubMedCrossRefGoogle Scholar
  20. Ferrari, C., Caldara, R., Romussi, M., Rampini, P., Telloli, P., Zaatar, S., and Curtarelli, G., 1978, Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion, Neuroendocrinology, 25: 319–328.PubMedCrossRefGoogle Scholar
  21. Finocchiaro, L.M.E., Arzt, E.S., Fernandez-Castelo, S., Criscuolo, M., Finkielman, S., and Nahmod, V.E., 1988, Serotonin and melatonin synthesis in peripheral blood mononuclear cells: stimulation by interferon-gamma as part of an immunomodulatory pathway, J. Interferon Res., 8: 705–716.PubMedCrossRefGoogle Scholar
  22. Flinn, J.H., Price, J.M., Yess, N., and Brown, R.R., 1964, Excretion of tryptophan metabolites by patients with rheumatoid arthritis, Arthr. Rheumatol., 7: 201–210.CrossRefGoogle Scholar
  23. Fuchs, D., and Wachter, H., 1988, Inflammatory joint disease and HIV infection, Brit. Med. J., 297: 422–423.PubMedCrossRefGoogle Scholar
  24. Goebel, F.D., Erfle, V., Piechowiak, H., Hien, P., Schloz, R., and Hehlmann, R., 1985, The relations of HTLV-III antibodies to neopterin and beta-2-microglobulin in the serum of patients with AIDS or persons at risk, in: “Biochemical and Clinical Aspects of Pteridines”, Vol. 4, Wachter, H., Curtius, H.C., and Pfleiderer, W., eds., de Gruyter, Berlin, pp. 319–333.Google Scholar
  25. Goldstein, D., Sielaff, K.M., Storer, B.E., Brown, R.R., Datta, S.P., Witt, P.L., Teitelbaum, A.P., Smalley, R.V., and Borden, E.C., 1989, Human biological response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-βser, J. Nat. Cancer Inst., 81: 1061–1068.PubMedCrossRefGoogle Scholar
  26. Grant, I., Atkinson, J.H., Hesselink, J.R., Kennedy, C.J., Richman, D.D., Spector, S.A., and McCutchan, J.A., 1987, Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections, Ann. Int. Med., 107: 828–836.PubMedGoogle Scholar
  27. Green, J.A., and Spruance, S.L., 1984, Acid-labile alpha interferon, New Engl. J. Med., 310: 922–923.CrossRefGoogle Scholar
  28. Hansotia, P., Peters, H., Bennet, M., and Brown, R.R., 1969, Chelation therapy in Wegner’s granulomatosis treatment with EDTA, Ann. Otol. Rhinol. Laryngol., 78: 388–402.PubMedGoogle Scholar
  29. Hasegawa, H., Kobayashi, T., and Ichiyama, A., 1988, 2,4-Diamino-6-hydroxypyrimidine (DAHP) induces intestinal disorder in mice: an animal model of serotonin deficiency by inhibition of tetrahydrobiopterin (THBP) synthesis, Biol. Chem. Hoppe-Seyler, 369: 532.Google Scholar
  30. Hayaishi, O., Yoshida, R., Takikawa, O., Yasui, H., 1984, Indoleamine dioxygenase — a possible biological function, in: “Progress in Tryptophan and Serotonin Research”, Schlossberger, H.G., Kochen, W., Linzen, B., and Steinhart, H., eds., de Gruyter, Berlin, pp. 33–42.Google Scholar
  31. Heyes, M.P., Rubinow, D., Lane, C., and Markey, S.P., 1989, Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome, Ann. Neurol., 26: 275–277.PubMedCrossRefGoogle Scholar
  32. Huber, C., Troppmair, J., Fuchs, D., Hausen, A., Lang, D., Niederwieser, D., Reibnegger, G., Swetly, P., Wachter, H., and Margreiter, R., 1985, Immune response-associated production of neopterin-release from macrophages under control of lymphokines, Transplant Proc., 17: 582–585.Google Scholar
  33. Jackson, J.C., Cross, R.J., Walker, R.F., Markesberry, W.R., Brooks, W.H., and Roszman, T.L., 1985, Influence of serotonin on the immune response, Immunology, 54: 505–512.PubMedGoogle Scholar
  34. Karnovsky, M.L., 1986, Muramyl peptides in mammalian tissues and their effects at the cellular level, Fed. Proc, 45: 2556–2560.PubMedGoogle Scholar
  35. Kull, F.C., Jr., Brent, D.A., Parikh, I., and Cuatrecasas, P., 1987, Chemical identification of a tumor-derived angiogenic factor, Science, 236: 843–845.PubMedCrossRefGoogle Scholar
  36. Lahdevirta, J., Maury, C.P.J., Teppo, A-M., and Repo, H., 1988, Elevated levels of circulating cachetin/tumor necrosis factor in patients with acquired immunodeficiency syndrome, Am. J. Med., 85: 289–291.PubMedCrossRefGoogle Scholar
  37. Larsson, M., Hagberg, L., Norkrans, G., and Forsman, A., 1989, Indoleamine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection, J. Neurosci. Res., 23: 441–446.PubMedCrossRefGoogle Scholar
  38. Launay, J-M., Copel, L., Callebert, J., Corvaia, N., Lepage, E., Bricare, F., Saal, F., and Peries, J., 1988, Decreased whole blood 5-hydroxytryptamine (serotonin) in AIDS patients, J. Acquired Immune Defic. Synd., 1: 324–325.Google Scholar
  39. Laurence, J., 1987, Dermatologic manifestations of HIV infection, Infections in Med., Jul/Aug, 241–251.Google Scholar
  40. Leyko, M.A., and Varesio, L., 1989, Role for tryptophan and its metabolites in the activation of macrophage tumor cytotoxicity, FASEB J., 3: A822.Google Scholar
  41. Lloyd, P., Stribling, D., and Pogson, C.I., 1983, Endotoxin and tryptophaninduced hypoglycaemia in rats, Biochem. Pharmacol., 31: 3571–3576.CrossRefGoogle Scholar
  42. Maclndoe, J.H., and Turkington, R.W., 1973, Stimulation of human prolactin secretion by intravenous infusion of L-tryptophan, J. Clin. Invest., 52: 1972–1978.CrossRefGoogle Scholar
  43. Manda, T., Nishigaki, F., Mor, J., and Shimomura, K., 1988, Important role of serotonin in the antitumor effects of recombinant tumor necrosis factor-a in mice, Cancer Res., 48: 4250–4255.PubMedGoogle Scholar
  44. McDonald, E.M., Mann, A.H., and Thomas, H.C., 1978, Interferons as mediators of psychiatric morbidity, Lancet, 2: 1175–1178.Google Scholar
  45. Melmed, R.N., Taylor, J.M.G., Detels, R., Bozorgmehri, M., and Fahey, J.L., 1989, Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS, J. Acquired Immune Defic, 2: 70–76.Google Scholar
  46. Monaco, F., Fumero, S., Mondino, A., and Mutani, R., 1979, Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative disdiseases, J. Neurol. Neurosurg. Psych., 42: 640–641.CrossRefGoogle Scholar
  47. Moon, R.J., 1971, Tryptophan oxygenase and tryptophan metabolism in endotoxin-poisoned and allopurinol-treated mice, Biochim. Biophys. Acta, 230: 324–348.CrossRefGoogle Scholar
  48. Moroni, F., Lombardi, G., Carla, V., Lai, S., Etienne, P., and Nair, N.P.V., 1986, Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure, J. Neurochem., 47: 1667–1671.PubMedCrossRefGoogle Scholar
  49. Murray, H.W., DePamphilis, J., Schooley, R.T., and Hirsch, M.S., 1988, Circulating interferon gamma in AIDS patients treated with interleukin-2, New Engl. J. Med., 318: 1538–1539.PubMedCrossRefGoogle Scholar
  50. Navia, B.A., Cho, E-S., Petito, C.K., and Price, R.W., 1986, The AIDS dementia complex: II. Neuropathology, Ann. Neurol., 19: 525–535.PubMedCrossRefGoogle Scholar
  51. Ozaki, Y., Edelstein, M.P., and Duch, D.S., 1987, The action of interferon and antiinflammatory agents on induction of indoleamine 2, 3-dioxygenase in human peripheral blood monocytes, Biochem. Biophys. Res. Commun., 144: 1147–1153.PubMedCrossRefGoogle Scholar
  52. Ozaki, Y., Edelstein, M.P., and Duch, D.S., 1988, Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferongamma, Proc. Natl. Acad. Sci. USA, 85: 1242–1246.PubMedCrossRefGoogle Scholar
  53. Pfefferkorn, E.R., 1984, Interferon-gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan, Proc. Natl. Acad. Sci. USA, 81: 908–912.PubMedCrossRefGoogle Scholar
  54. Pfefferkorn, E.R., Eckel, M., and Rebhun, S., 1986, Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan, Mol. Biochem. Parasitol., 20: 215–224.PubMedCrossRefGoogle Scholar
  55. Price, J.M., Brown, R.R., Rukavina, J.G., Mendelson, C., and Johnson, S.A.M., 1957, Scleroderma (Acrosclerosis). II. Tryptophan metabolism before and during treatment by chelation (EDTA), J. Invest. Dermatol., 29: 289–298.PubMedGoogle Scholar
  56. Rapoport, M.I., and Beisel, W.R., 1971, Studies of tryptophan metabolism in experimental animals and man during infectious illness, Am. J. Clin. Nutr., 24: 807–814.PubMedGoogle Scholar
  57. Reibnegger, G., Bollbach, R., Fuchs, D., Hausen, A., Judmaier, G., Prior, C., Rotthauwe, H.W., Werner, E.R., and Wachter, H., 1986, A simple index relating clinical activity in Crohn’s disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters, Imnmnobiology, 173: 1–11.CrossRefGoogle Scholar
  58. Roberts, J., Schmid, F.A., and Rosenfeld, H.J., 1979, Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, L-tryptophan, and L-histidine, Cancer Treatment Rep., 63: 1045–1054.Google Scholar
  59. Spampinato, S., Locatelli, V., Cocchi, D., Vicentini, L., Bajusz, S., Ferri, S., and Müller, E.E., 1979, Involvement of brain serotonin in the prolactin-releasing effect of opioid peptides, Endocrinology, 105: 163–170.PubMedCrossRefGoogle Scholar
  60. Sternberg, E.M., Trial, J., and Parker, C.W., 1986, Effect of serotonin on murine macrophages: suppression of Ia expression by serotonin and its reversal by 5-HT2 serotonergic receptor antagonists, J. Immunol., 137: 276–282.PubMedGoogle Scholar
  61. Sternberg, E.M., Van Woert, M.H., Young, S.N., Magnussen, I., Baker, H., Gauthier, S., and Osterland, C.K., 1980, Development of a sclerodermalike illness during therapy with L-5-hydroxytryptophan and carbidopa, New Engl. J. Med., 303: 782–787.PubMedCrossRefGoogle Scholar
  62. Takikawa, O., Kuroiwa, T., Yamazaki, F., and Kido, R., 1988, Mechanism of interferon-gamma action; characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity, J. Biol. Chem., 263: 2041–2048.PubMedGoogle Scholar
  63. Takikawa, O., Yoshida, R., Kido, R., and Hayaishi, O., 1986, Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase, J. Biol. Chem., 261: 3648–3653.PubMedGoogle Scholar
  64. Talal, N., 1985, Interleukins, interferon and rheumatic disease, Clin. Rheum. Dis., 11: 633–644.PubMedGoogle Scholar
  65. Tutton, P.J.M., and Barkla, D.H., 1987, Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells, Anticancer Res., 7: 1–12.PubMedGoogle Scholar
  66. Vivian, V.M., Brown, R.R., Price, J.M., and Reynolds, M.S., 1966, Some aspects of tryptophan and niacin metabolism in young women consuming a low tryptophan diet supplemented with niacin, J. Nutr., 88: 93–99.PubMedGoogle Scholar
  67. Wachter, H., Fuchs, D., Hausen, A., Huber, C., Knosp, O., Reibnegger, G., and Spira, T., 1983, Elevated urinary neopterin levels in patient’s with the acquired immunodeficiency syndrome (AIDS), Hoppe Seyler’s Z. Physiol. Chem., 364: 1345–1346.PubMedCrossRefGoogle Scholar
  68. Werner, E.R., Bitterlich, G., Fuchs, D., Hausen, A., Reibnegger, G., Szabo, G., Dierich, M.P. and Wachter, H., 1987, Human macrophages degrade tryptophan upon induction by interferon-gamma, Life Sci., 41: 273–280.PubMedCrossRefGoogle Scholar
  69. Werner, E.R., Fuchs, D., Hausen, A., Jaeger, H., Reibnegger, G., Werner-Felmayer, G., Dierich, M.P., and Wachter, H., 1988, Tryptophan degradation in patients infected by human immunodeficiency virus, Biol. Chem. Hoppe-Seyler, 369: 337–340.PubMedCrossRefGoogle Scholar
  70. Werner, E.R., Fuchs, D., Hausen, A., Lutz, H., Reibnegger, G., and Wachter, H., 1985, Interferon-gamma-induced in vitro-excretion of neopterin and 3-hydroxyanthranilic acid by human macrophages, in: “Biochemical and Clinical Aspects of Pteridines”, Vol. 4, Wachter, H., Curtius H.C., and Pfleiderer, W., eds., de Gruyter, Berlin, pp. 473–406.Google Scholar
  71. Wooley, P.V., III, Dion, R.L. and Bono, V.H., Jr., 1974, Effects of tryptophan deprivation on L1210 cells in culture, Cancer Res., 34: 1010–1014.Google Scholar
  72. Yasui, H., Takai, K., Yoshida, Y., and Hayaishi, O., 1986, Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients, Proc. Natl. Acad. Sci. USA, 83: 6622–6626.PubMedCrossRefGoogle Scholar
  73. Yoshida, R., and Hayaishi, O., 1978, Induction of pulmonary indo1eamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide, Proc. Natl. Acad. Sci. USA, 75: 3998–4001.PubMedCrossRefGoogle Scholar
  74. Yoshida, R., Imanishi, J., Oku, T., Kishida, T., and Hayaishi, O., 1981, Induction of pulmonary indoleamine 2,3-dioxygenase by interferon, Proc. Natl. Acad. Sci. USA, 78: 129–132.PubMedCrossRefGoogle Scholar
  75. Yoshida, R., Park, S.W., Yasui, H., and Hayaishi, O., 1988, Tryptophan degradation in transplanted tumor cells undergoing rejection, J. Immunol., 141: 2819–2823.PubMedGoogle Scholar
  76. Yoshida, R., Urade, M., Tokuda, M., and Hayaishi, O., 1979, Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection, Proc. Natl. Acad. Sci. USA, 76: 4084–4088.PubMedCrossRefGoogle Scholar
  77. Zolla-Pazner, S., William, D., El-Sadr, W., Marmor, M., and Stahl, R., 1984, Quantitation of β-2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome, J. Am. Med. Assoc., 251: 2951–2955.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • R. R. Brown
    • 1
  • Y. Ozaki
    • 1
  • S. P. Datta
    • 3
  • E. C. Borden
    • 2
  • P. M. Sondel
    • 1
  • D. G. Malone
    • 2
  1. 1.Departments of Human OncologyUniversity of Wisconsin Medical SchoolMadisonUSA
  2. 2.Departments of MedicineUniversity of Wisconsin Medical SchoolMadisonUSA
  3. 3.University of Wisconsin-ParksideKenoshaUSA

Personalised recommendations